Medicaid GLP-1 coverage by state: the 2026 tracker
What we evaluated: state Medicaid coverage of GLP-1 medications for obesity, against the primary tracker (KFF) and dated state bulletins
Date verified: January 2026 (KFF); state actions through April 2026
Direct answer: 13 state Medicaid fee-for-service programmes cover GLP-1s for obesity as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all eliminated coverage on January 1, 2026. Massachusetts is scheduled to end coverage on July 1, 2026. North Carolina reinstated coverage in December 2025 and Tennessee reversed its exclusion in August 2025
Necessary qualification: you will see other sites claim 36 or 38 states. Those counts include managed-care plans, diabetes-only coverage, or 'Saxenda only' treated as equivalent to full coverage. Even where obesity coverage is excluded, four federal rules still give you a path — read those first
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Every dated state action we can source
These are the only state Medicaid changes for which we hold a dated, citable bulletin. Four states cut coverage on a single day — 1 January 2026 — taking the national total from 16 to 13. We do not fill in the other states with a guess.
| State | Effective | What happened | Source |
|---|---|---|---|
| Tennessee | August 1, 2025 | TennCare reversed its long-standing exclusion on August 1, 2025 | TennCare pharmacy bulletin |
| North Carolina | December 12, 2025 | North Carolina REINSTATED coverage on December 12, 2025 | NC Medicaid PDL, January 2026 |
| California | January 1, 2026 | Medi-Cal ELIMINATED weight-loss GLP-1 coverage on January 1, 2026 | Medi-Cal Rx Contract Drugs List; KFF, January 2026 |
| Pennsylvania | January 1, 2026 | Pennsylvania eliminated adult obesity GLP-1 coverage on January 1, 2026 | PA DHS; KFF, January 2026 |
| New Hampshire | January 1, 2026 | New Hampshire eliminated obesity GLP-1 coverage on January 1, 2026 | KFF, January 2026 |
| South Carolina | January 1, 2026 | South Carolina eliminated obesity GLP-1 coverage on January 1, 2026 | KFF, January 2026 |
| Michigan | January 2026 | Michigan sharply restricted coverage in January 2026 | MDHHS provider notification L 25-73 |
| Massachusetts | March 12, 2026 | MassHealth is scheduled to END weight-loss GLP-1 coverage on July 1, 2026 | MassHealth Pharmacy Facts 271, March 12, 2026 |
Four federal rules that apply in every state
These are the most useful facts on this page, and they are true regardless of what your state decided. If your state has excluded obesity coverage, read these before concluding you have no path.
Why published 50-state tables contradict each other
The discrepancy comes from counting different things: fee-for-service programmes versus managed-care plans; diabetes coverage versus obesity coverage; and 'covers Saxenda only, with BMI 35+ and multiple comorbidities' being counted identically to 'covers Wegovy and Zepbound'.
We follow KFF, the primary tracker, which counts fee-for-service obesity coverage: 13 states as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all cut coverage on January 1. Where we hold a dated state bulletin we cite it. Where we do not, we say so rather than filling the cell with a guess.
If you have no coverage: what cash actually costs now
An FDA-approved, quality-verified, manufacturer-supplied medication at $149, against a compounded market that mostly runs $169-$399. The catch is dose escalation — Foundayo rises to $199, then $299, then $349 as you titrate, and at the top doses it has its own 45-day refill rule (it drops back to $299 if you refill in time). But for a starting patient, or anyone maintaining on a lower dose, the brand oral pill is now among the cheapest legitimate options in the entire category — and almost no comparison site has caught up.
The assumption that losing Medicaid coverage means paying $1,300 a month is out of date. Brand Zepbound is $299–$449 through LillyDirect. Brand Wegovy is $349 through NovoCare, and the oral Wegovy tablet is $149. Foundayo, Lilly's FDA-approved oral GLP-1, starts at $149. See the full pricing database.
All 50 states
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Frequently asked questions
How many states cover GLP-1s for weight loss under Medicaid?
13, as of January 2026, per KFF — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all eliminated coverage on January 1. You will see other numbers (36, 38) on other sites; those count managed-care plans, diabetes coverage, or 'Saxenda only' the same as full coverage.
My state doesn't cover it. Do I really have no options?
Probably not. Four federal rules still apply. Type 2 diabetes coverage is federally required everywhere. If you are under 21, EPSDT law protects you even where adults are excluded. Zepbound is separately approved for sleep apnea, and Wegovy for cardiovascular risk and MASH — different diagnosis codes that survive an obesity cut. And cash-pay is now far cheaper than most people think: the FDA-approved Foundayo oral pill is $149/month.
Which states changed most recently?
Massachusetts is scheduled to END weight-loss coverage on July 1, 2026 — if you are covered there, verify your renewal timeline. California, New Hampshire, Pennsylvania and South Carolina all cut on January 1, 2026. Michigan sharply restricted. North Carolina reinstated on December 12, 2025, and Tennessee reversed its exclusion in August 2025.
Why do 50-state Medicaid tables disagree with each other?
Because they count different things — fee-for-service versus managed care, obesity versus diabetes, and 'covers Saxenda with BMI 35+ and multiple comorbidities' counted identically to 'covers Wegovy and Zepbound'. We follow KFF and cite dated state bulletins, and where we have neither we say so.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s", January 2026. The primary tracker; the source of the 13-state count.
- Medi-Cal Rx Contract Drugs List — California, effective January 1, 2026.
- MDHHS provider notification L 25-73 — Michigan restriction.
- MassHealth Pharmacy Facts 271, March 12, 2026 — scheduled July 1, 2026 change.
- NC Medicaid Preferred Drug List, January 2026 — reinstatement of GLP-1 weight-management class.
- TennCare pharmacy bulletin — August 1, 2025 coverage expansion.
- Federal EPSDT requirements; FDA approvals for Zepbound (OSA, December 2024) and Wegovy (CV risk, March 2024; MASH, August 2025).
- Our source hierarchy. We do not treat an affiliate comparison site as evidence.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded tirzepatide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.